Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

2010 ◽  
Vol 122 (3) ◽  
pp. 609-617 ◽  
Author(s):  
Bostjan Seruga ◽  
Eitan Amir
Keyword(s):  
Cytochrome P450 ◽  
Meta Analysis ◽  
Tamoxifen Therapy ◽  
Adjuvant Tamoxifen ◽  
Cytochrome P450 2D6 ◽  
P450 2D6 ◽  
Adjuvant Tamoxifen Therapy

Cytochrome P450 2D6 mutation in Turkish women receiving adjuvant tamoxifen.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e11098-e11098
Author(s):  
M. T. Kutluk ◽  
M. K. Altundag ◽  
Y. Y. Ozisik ◽  
Ç. Demir ◽  
S. Agbaba ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Adjuvant Tamoxifen ◽  
Cytochrome P450 2D6 ◽  
Turkish Women ◽  
P450 2D6

Cytochrome P450 2D6 polymorphisms of Thai patients with breast cancer and their outcomes of adjuvant tamoxifen.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11037-e11037 ◽  
Author(s):  
K. Pechatanan ◽  
S. Jaruhathai ◽  
T. Ativitavas ◽  
T. Sirisinha ◽  
R. Panvichian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Adjuvant Tamoxifen ◽  
Cytochrome P450 2D6 ◽  
P450 2D6

Adverse effects of adjuvant tamoxifen treatment on bone mineral density in premenopausal breast cancer patients: A systematic review and meta-analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12500-e12500
Author(s):  
Chihwan Cha ◽  
Soo Jin Lee ◽  
Hanpyo Hong ◽  
Yun Young Choi ◽  
Min Sung Chung
Keyword(s):  
Breast Cancer ◽  
Lumbar Spine ◽  
Bone Loss ◽  
Meta Analysis ◽  
Premenopausal Women ◽  
Tamoxifen Therapy ◽  
Tamoxifen Treatment ◽  
Adjuvant Tamoxifen ◽  
Mineral Density ◽  
Adjuvant Tamoxifen Therapy

e12500 Background: It is well known that adjuvant tamoxifen treatment for breast cancer in postmenopausal women decreases bone loss. However, the adverse effect of adjuvant tamoxifen therapy for bone mineral density (BMD) in premenopausal breast cancer patients remains uncertain. This meta-analysis aimed to assess the effects of adjuvant tamoxifen therapy on BMD changes in premenopausal women with primary breast cancer. Methods: Through April 2020, studies reporting BMD changes of lumbar spine or hip in premenopausal women with primary breast cancer treated with adjuvant tamoxifen were collected from EMBASE and PubMed. The pooled analysis was performed using random effects model of the standardized mean difference (SMD) of BMD in patients. Results: A total of 1,432 premenopausal patients from eight studies were included in the pooled analysis. After 3 years of median follow up, adjuvant tamoxifen therapy decreased BMD by as much as SMD of -0.79 [95% confidence interval (CI); -1.25 to -0.33, P < 0.01] at lumbar spines and -0.38 at hip (95%CI; -0.88 to 0.12, P > 0.05). Compared with patients received tamoxifen alone, patients who received combination therapy with chemotherapy or ovarian function suppression (OFS) showed decreased bone loss at lumbar spine (SMD -1.17 with 95%CI -1.59 to -0.75, -0.43 with 95%CI -2.26 to 1.40, and -0.75 with 95%CI -1.38 to -0.13, respectively). Conclusions: Our meta-analysis revealed that premenopausal women who received adjuvant tamoxifen treatment showed significant bone loss over a period of time, especially at lumbar spine. However, tamoxifen attenuated bone loss in those who received tamoxifen after chemotherapy or along with OFS.[Table: see text]

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

2006 ◽  
Vol 101 (1) ◽  
pp. 113-121 ◽  
Author(s):  
Matthew P. Goetz ◽  
Stacey K. Knox ◽  
Vera J. Suman ◽  
James M. Rae ◽  
Stephanie L. Safgren ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Adjuvant Tamoxifen ◽  
Cytochrome P450 2D6 ◽  
The Impact ◽  
P450 2D6

scholarly journals Breast cancer: Role of pharmacogenetics in tamoxifen therapy

2016 ◽  
Vol 1 (1) ◽  
pp. 10
Author(s):  
Smriti Mishra ◽  
Manish Manish
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Genetic Polymorphism ◽  
Clinical Outcome ◽  
Tamoxifen Therapy ◽  
Uridine Diphosphate ◽  
Cytochrome P450 2D6 ◽  
Cytochrome P450 3A ◽  
P450 2D6

<p><span>The role of pharmacogenetics in the personalization of tamoxifen therapy has relevance in the management of breast cancer. Since Tamoxifen is a pro-drug, genetic polymorphism in Phase I and Phase II drug metabolizing enzymes involved in the bioconversion of tamoxifen to therapeutically active metabolites is critical in determining therapeutic efficacy and adverse drug reactions of the therapy in breast cancer patients. In this review, the role of pharmacogenetics in the personalization of tamoxifen therapy has been discussed. Since, metabolism of tamoxifen by Cytochrome P450 2D6 is significant in determining the therapeutic efficacy of the drug, most of the clinical evidence on tamoxifen pharmacogenetics have been correlated with cytochrome p450 2D6 genetic polymorphism. However, there is discordance in the clinical data, and one of the reasons is the incomplete analysis of all the alleles of cytochrome p450 2D6. International Tamoxifen Pharmacogenomics Consortium has been formed to assess   the discordance. There are also clinical evidences associating genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome of tamoxifen therapy. However, associations of genetic polymorphism in cytochrome P450 3A, 2C9, 2C19, Uridine diphosphate –glucuronosyltransferases and Sulfotransferases with clinical outcome in populations of different ethnicity are unexplored. Evidences on  the association of genetic polymorphisms and the clinical outcome have been summarized in the Table.  Since cost, statistically significant sample population size, labor and ethical issues are the major concerns of a pharmacogenetic investigation; the significance of bottom-up approach in pharmacogenetics has been discussed.</span></p>

scholarly journals Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

2009 ◽  
Vol 9 (4) ◽  
pp. 258-264 ◽  
Author(s):  
J M Rae ◽  
◽  
M J Sikora ◽  
N L Henry ◽  
L Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cytochrome P450 ◽  
Cancer Patients ◽  
Tamoxifen Therapy ◽  
Cytochrome P450 2D6 ◽  
Breast Cancer Patients ◽  
P450 2D6
Sign in / Sign up

Export Citation Format

Share Document